The Claim

Lean body mass loss accounts for approximately 28% of total weight reduction in adults with obesity or diabetes treated with glucagon-like peptide-1 receptor agonists or sodium-glucose co-transporter-2 inhibitors, and this proportion is similar to that observed with diet-induced weight loss, indicating that the loss is proportional to overall caloric deficit rather than a unique pharmacological effect.

Source: The Effects of Glucagon‐Like Peptide‐1 Receptor Agonists and Sodium‐Glucose Co‐Transporter‐2 Inhibitors on Lean Body Mass in Humans: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
53score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

How it works
1 study reviewed
In plain English

In adults with obesity or diabetes, about 28% of weight lost from GLP-1 receptor agonists or SGLT2 inhibitors comes from lean body mass, which is the same proportion seen when people lose weight through dieting, suggesting the loss reflects total calorie reduction rather than a drug-specific effect.

See the scientific wording

Across both glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors, lean body mass loss accounts for approximately 28% of total weight reduction in adults with obesity or diabetes, a proportion similar to that observed with diet-induced weight loss, suggesting the loss is proportional to overall caloric deficit rather than a unique pharmacological effect.

Why this might work

When the body loses calories through reduced food intake or glucose excretion in urine, it breaks down muscle tissue to make energy and glucose, causing a proportional loss of lean body mass.

Verified mechanismbased on 1 study

What the research says

1 study
  1. Study: The Effects of Glucagon‐Like Peptide‐1 Receptor Agonists and Sodium‐Glucose Co‐Transporter‐2 Inhibitors on Lean Body Mass in Humans: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials

    When people with obesity or diabetes lose weight using these two types of drugs, about 28% of the weight lost comes from muscle and bone — just like when people lose weight by eating less. The study found this exact number, so it supports the claim.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.